Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein regulator of cytokinesis 1 (PRC1)
- Target
- PRC1
- Molecular classification
- Non-motor microtubule-associated protein (MAP), Cytokinesis regulator, Other
01
Overview
Protein regulator of cytokinesis 1 (PRC1) is a non-motor microtubule-associated protein essential for central spindle formation and cytokinesis during cell division. It cross-links antiparallel microtubules at the spindle midzone, facilitating proper cell cleavage. PRC1 is tightly regulated by cell cycle-dependent phosphorylation and interacts with proteins such as Kinesin-4 and the centralspindlin complex. Dysregulation or overexpression of PRC1 is linked to genome instability, altered tumor immune environments, and poor prognosis in multiple cancer types, making it a candidate prognostic biomarker and a potential, though not yet clinically validated, therapeutic target.
- Other names
- ASE1MAP65Anaphase spindle elongation 1 homologProtein regulating cytokinesis 1SPD-1 (in C. elegans)Feo (in D. melanogaster)
02
Mechanism of action
Potential mechanisms for future drugs may include inhibition of microtubule bundling, disruption of PRC1 dimerization, modulation of PRC1 phosphorylation, and interference with its protein-protein interactions (e.g., Kinesin-4, centralspindlin complex)
03
Biological functions
CytokinesisCell cycle regulationMicrotubule cross-linking and bundlingSpindle midzone assemblyGenome stabilityRegulation of mitotic exit
04
Disease associations
Cancer (including liver, colon, breast, prostate)Prognostic marker in several tumorsImmune microenvironment regulationGenome instability
05
Safety considerations
Targeting PRC1 may impair normal cytokinesis and cell division, posing a risk of toxicity to proliferative healthy tissuespotential for genomic instability or off-target effects on cell cycle and microtubule functionsafety of PRC1-specific inhibitors in humans remains unknown
06
Interacting drugs
There are currently no approved or clinically validated drugs specifically targeting PRC1. It is a proposed potential therapeutic target; pharmacological strategies to target PRC1 are under investigation
07
Biomarkers
PRC1 mRNA/protein overexpression as a prognostic marker in cancers (e.g., liver, breast, colon, prostate)PRC1 methylation status (associated with clinical outcomes)Correlation with immune checkpoint gene expression (PD-L1, CTLA4, etc.)
Beyond the preview
Go deeper on Protein regulator of cytokinesis 1 (PRC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein regulator of cytokinesis 1 (PRC1).